Tag: Marathon Pharmaceuticals

February 10, 2017 Off

Muscular Dystrophy Association welcomes FDA’s grant for Marathon’s Emflanza

The Muscular Dystrophy Association said yesterday it welcomed news of the U.S. Food and Drug Administration’s decision to grant approval for deflazacort (Emflaza), developed by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.

February 9, 2017 Off

FDA approves Marathon Pharmaceuticals’s orphan drug

By Dino Mustafić

The U.S. Food and Drug Administration (FDA) has approved Marathon Pharmaceuticals’s Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness.